Nordic Issuing

Ongoing case

RhoVac AB

Back to all cases

RhoVac AB

17 Mar - 31 Mar 2022Rights issue

RhoVac is a pharmaceutical company dedicated to immuno-oncology, signifying that the body’s own immune system is stimulated to identify and destroy cancer cells. The primary focus of RhoVac is to develop a cancer therapy that targets metastatic cells to prevent cancer recurrence and progression after primary tumour therapy. RhoVac was founded as a private company in Denmark 2007. In the following years the first steps in terms of development of the drug candidate, RV001, were taken. In 2015 the Swedish RhoVac AB, now headquarters, was founded, and in 2016 the company was listed on “Spotlight Stock Market”.

Read more on the company's website

The offer in summary

Record date: 11 March 2022

Subscription period: 17 March 2022 - 31 March 2022

Subscription rights: One (1) existing share in the Company entitles to one (1) unit right. Sixty-one (61) unit rights entitles to one (1) unit which consists of two (2) convertibles. One (1) convertible entitles to one (1) newly issued share.

Subscription price: 80.00 SEK per unit

The offer: Maximum 624 494 convertibles which corresponds to about 25 MSEK

Trading with unit rights: 17 March 2022 - 28 March 2022

Marketplace: Spotlight Stock Market

Financial advisor: Sedermera Corporate Finance

Subscribe through Avanza here

Subscribe through Nordnet here


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.